The Company may sell, from time to time, at its option, shares of the Company’s common stock, through or to Jefferies, as sales agent or principal (the “ATM Offering”).
Currently, we rely on and have agreements with a single third-party contract manufacturer to supply the zervimesine drug substance and with a single third-party contract manufacturer to manufacture c…
On December 16, 2025, the Company delivered written notice to B. Riley Securities, Inc. to terminate the Previous Sales Agreement, effective December 18, 2025.
which registered the offering, issuance and sale of up to $ 300.0 million of various equity and debt securities and up to $ 75,000 of common stock pursuant to an at-the-market equity offering program…
tured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from th…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: tured, or disagrees with the prom…
the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the pa…
Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from CGTX graph: Reciprocal relationship from ORAN…
Cognition Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CGTX-DEBT
Debt stack $638,000
90%
Market cache reports total debt of $638,000.
CGTX-DEBT-8615
Warrants outstanding: 34000
90%
xbrl warrant detail from xbrl 2021-12-31.
CGTX-DEBT-8616
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
Cognition Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Cognition Therapeutics, Inc..
Cognition Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
CGTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 75 tracked holders.
Cognition Therapeutics, Inc. Extended Supply Chain Network